Tuberculosis treatment failure: what are the risk factors? A comprehensive literature review
Keywords:
tuberculosis management, tuberculosis risk factors, tuberculosis treatment outcomeAbstract
Tuberculosis (TB), induced by Mycobacterium tuberculosis, is a significant global health concern. It affects approximately 25% of the global population and ranks among the primary causes of mortality from infectious diseases. Notwithstanding progress, TB treatment and diagnosis continue to encounter substantial obstacles, such as restricted access to precise diagnostics and efficacious therapies. By 2035, international objectives seek to diminish tuberculosis-related fatalities by 95% and enhance treatment accessibility. Multiple factors affect the success of TB treatment, including personal behaviors, social and demographic circumstances, and concurrent health conditions. Critical risk factors for suboptimal treatment outcomes encompass low body mass index, tobacco use, substance abuse, and various demographic variables, including gender, age, unemployment, geographic location, and migration status. Co-infections with HIV, diabetes, chronic kidney disease, and COVID-19 are associated with increased rates of treatment failure. Supplementary challenges, including loss to follow-up and drug-resistant TB, elevate the probability of treatment failure. This review’s findings intend to furnish essential insights for policymakers, healthcare professionals, and TB control programs, enhancing strategies and interventions. The primary objective is to improve the efficacy of TB management globally, with an emphasis on attaining superior treatment outcomes, particularly in the most underserved regions.
References
1. Furin J, Cox H, Pai M. Tuberculosis. Lancet 2019;393:1642-56.
2. Zaman K. Tuberculosis: a global health problem. J Health Popul Nutr 2010;28:111-3
3. Friedman LN, Dedicoat M, Davies PD. Clinical tuberculosis. 6th ed. 2020;53.
4. Allué-Guardia A, García JI, Torrelles JB. Evolution of drug-resistant Mycobacterium tuberculosis strains and their adaptation to the human lung environment. Front Microbiol 2021;12:612675.
5. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
6. World Health Organization. Tuberculosis [Internet]. -Available from: https://www.who.int/news-room/fact-sheets
/detail/tuberculosis
7. World Health Organization. WHO End TB strategy [Internet]. 2015. Available from: https://www.who.int/tb
/post2015_strategy/en/
8. Cox H, Nicol MP. Tuberculosis eradication: renewed commitment and global investment required. Lancet Infect Dis 2018:228-9.
9. World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
10. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004:286-98.
11. Leung CC, Lam TH, Chan WM, Yew WW, Ho KS, -Leung G, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007;167:1297-304.
12. Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol 2010:149-55.
13. Cegielski JP, Arab L, Cornoni-Huntley J. Nutritional risk factors for tuberculosis among adults in the United States, 1971–1992. Am J Epidemiol 2012;176:409-22.
14. Yen YF, Hu HY, Lee YL, Ku PW, Lin IF, Chu D, et al. Obesity/overweight reduces the risk of active tuberculosis: a nationwide population-based cohort study in Taiwan. Int J Obes (Lond) 2017;41:971-5.
15. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-46.
16. Zhang H, Li X, Xin H, Li H, Li M, Lu W, et al. -Association of body mass index with the tuberculosis -infection: a -population-based study among 17796 adults in rural China. Sci Rep 2017;7:41933.
17. Kathamuthu GR, Sridhar R, Baskaran D, Babu S. Low body mass index has minimal impact on plasma levels of cytokines and chemokines in tuberculous lymphadenitis. J Clin Tuberc Other Mycobact Dis 2020;20:100163.
18. Kim SJ, Ye S, Ha E, Chun EM. Association of body mass index with incident tuberculosis in Korea. PLoS One 2018;13:e0195104.
19. Cai N, Luo W, Ding L, Chen L, Huang Y. Obesity-related indicators and tuberculosis: a Mendelian randomization study. PLoS One 2024;19:e0297905.
20. Oyewusi L, Zeng C, Seung KJ, Mpinda S, Kunda M, Mitnick CD, et al. Low body mass index as a predictor of sputum culture conversion and treatment outcomes among patients receiving treatment for multidrug-resistant tuberculosis in Lesotho. Glob Health Action 2024;17:2305930.
21. Koethe JR, von Reyn CF. Protein-calorie malnutrition, macronutrient supplements, and tuberculosis. Int J Tuberc Lung Dis 2016;20:857-63.
22. Költringer FA, Annerstedt KS, Boccia D, Carter DJ, Rudgard WE. The social determinants of national tuberculosis incidence rates in 116 countries: a longitudinal ecological study between 2005–2015. BMC Public Health 2023;23:337.
23. Feldman C, Theron AJ, Cholo MC, Anderson R. Cigarette smoking as a risk factor for tuberculosis in adults: epidemiology and aspects of disease pathogenesis. Pathogens 2024;13:151.
24. Chan ED, Keane J, Iseman MD. Should cigarette smoke exposure be a criterion to treat latent tuberculous infection? Am J Respir Crit Care Med 2010;182:990-2.
25. Bay JG, Patsche CB, Svendsen NM, Gomes VF, Rudolf F, Wejse C. Tobacco smoking impact on tuberculosis treatment outcome: an observational study from West Africa. Int J Infect Dis 2022;124:S50-S5.
26. Gambhir HS, Kaushik RM, Kaushik R, Sindhwani G. Tobacco smoking-associated risk for tuberculosis: a case-control study. Int Health 2010;2:216-22.
27. Pai M, Mohan A, Dheda K, Leung CC, Yew WW, Christopher DJ, et al. Lethal interaction: the colliding epidemics of tobacco and tuberculosis. Expert Rev Anti Infect Ther 2007;5:385-91.
28. Kaliner E, Bornstein S, Kabha D, Lidji M, Sheffer R, Mor Z. A retrospective cohort analysis of treatment outcomes of patients with tuberculosis who used substances in Tel Aviv, Israel. Alcohol Alcohol 2024;59:agad073
29. Bishwakarma R, Kinney WH, Honda JR, Mya J, Strand MJ, Gangavelli A, et al. Epidemiologic link between tuberculosis and cigarette/biomass smoke exposure: limitations despite the vast literature. Respirology 2015;20:556-68.
30. Smith GS, Van Den Eeden SK, Baxter R, Shan J, Van Rie A, Herring AH, et al. Cigarette smoking and pulmonary tuberculosis in Northern California. J Epidemiol Community Health 2015;69:568-73.
31. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023. -
Available from: https://iris.who.int/bitstream/handle/10665/373828/9789240083851-eng.pdf
32. Imtiaz S, Shield KD, Roerecke M, Samokhvalov A. Alcohol consumption as a risk factor for tuberculosis: meta--analyses and burden of disease. Eur Respir J 2017;50:1700216.
33. Myers B, Bouton TC, Ragan EJ, White LF, McIlleron H, Theron D, et al. Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol. BMC Infect Dis 2018;18:488.
34. Volkmann T, Moonan PK, Miramontes R, Oeltmann JE. Tuberculosis and excess alcohol use in the United States, 1997–2012. Int J Tuberc Lung Dis 2015;19:111-9.
35. Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013;208:1464-73.
36. Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother 2015;59:38-47.
37. Swaminathan S, Pasipanodya JG, Ramachandran G, -Hemanth Kumar AK, Srivastava S, Deshpande D, et al. Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests. Clin Infect Dis 2016;63:S63-S74.
38. Necho M, Tsehay M, Seid M, Zenebe Y, Belete A, Gelaye H, et al. Prevalence and associated factors for alcohol use disorder among tuberculosis patients: a systematic review and meta-analysis study. Subst Abuse Treat Prev Policy 2021;16:2.
39. Bayigga J, Kakai I, Odongpiny EAL, Ddungu A, Semakula L, Nansereko M, et al. Alcohol use disorder among people diagnosed with tuberculosis in a large urban case-finding project in central Uganda: prevalence, associated factors and challenges to treatment adherence. Subst Abuse Treat Prev Policy 2025;20:10.
40. Khaitan A, Rai SK, Krishnan A, Kant S, Khilnani GC. “I would rather die drinking than take the medicine”: role of alcohol use disorder in loss-to-follow-up of tuberculosis treatment in a rural area of Ballabgarh, Haryana. Indian J Community Med 2024;49:153-6.
41. Jinyi W, Zhang Y, Wang K, Peng P. Global, regional, and national mortality of tuberculosis attributable to alcohol and tobacco from 1990 to 2019: a modelling study based on the Global Burden of Disease study 2019. J Glob Health 2024;14:4023.
42. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://iris.who.int/bitstream/handle/10665/363752/9789240061729-eng.pdf.
43. United Nations Office on Drugs and Crime. World drug report 2021. Sales No. E.21.XI.8. Available from: https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_2.pdf.
44. United Nations Office on Drugs and Crime. World drug report 2020. Sales No. E.20.XI.6. Available from: https://wdr.unodc.org/wdr2020/field/WDR20_Booklet_2.pdf.
45. Aho J, Lacroix C, Bazargani M, Milot DM, Sylvestre JL, Pucella E, et al. Outbreak of tuberculosis among substance users and homeless people in Greater Montréal, Canada, 2003–2016. Can Commun Dis Rep 2017;43:72-6.
46. Coutinho SE, Lima de Braga RS, Santos AK, Velho JS, Rossato Silva D. Smoking cessation among tuberculosis patients during the coronavirus disease-2019 pandemic. Monaldi Arch Chest Dis 2024.
47. Rupani MP. Need for implementation of national framework for tuberculosis-alcohol (TB-alcohol) collaborative activities in India: drifting closer to TB elimination by 2025. Indian J Tuberc 2024;71:108-9.
48. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics 2019;13:2.
49. Hertz D, Schneider B. Sex differences in tuberculosis. Semin Immunopathol 2019;41:225-37.
50. Pape S, Karki SJ, Heinsohn T, Brandes I, Dierks ML, Lange B. Tuberculosis case fatality is higher in male than female patients in Europe: a systematic review and meta-analysis. Infection 2024;52:1775-86.
51. Yang WT, Gounder CR, Akande T, De Neve JW, McIntire KN, Chandrasekhar A, et al. Barriers and delays in tuberculosis diagnosis and treatment services: does gender matter? Tuberc Res Treat 2014;2014:461935.
52. Horton KC, MacPherson P, Houben RM, White RG, -Corbett EL. Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med 2016;13:e1002119.
53. Chikovore J, Pai M, Horton KC, Daftary A, Kumwenda MK, Hart G, et al. Missing men with tuberculosis: the need to address structural influences and implement targeted and multidimensional interventions. BMJ Glob Health 2020;5:e002255.
54. Shayan NA, Rahimi A, Stranges S, Thind A. Exploring sex differences in risk factors and quality of life among tuberculosis patients in Herat, Afghanistan: a case-control study. Int J Public Health 2024;69:1606554.
55. Oyageshio OP, Myrick JW, Saayman J, van der Westhuizen L, Al-Hindi DR, Reynolds AW, et al. Strong effect of demographic changes on tuberculosis susceptibility in South Africa. PLOS Glob Public Health 2024;4:e0002643.
56. AlOsaimi HM, Alshammari MK, Almijlad GK, Alotaibi NM, Alqahtani DA, Alshamrani MM, et al. Prevalence, clinical characteristics and determinants of unsuccessful treatment outcomes among pulmonary tuberculosis patients: a 5-year registry-based retrospective cohort study. Patient Relat Outcome Meas 2024;15:187-98.
57. Caraux-Paz P, Diamantis S, de Wazières B, Gallien S. -Tuberculosis in the elderly. J Clin Med 2021;10:5888.
58. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet 2015;385:1799-801.
59. Golsha R, Mazandarani M, Sohrabi A, Shirzad-Aski H, Kamalinia H, Rezaeifar A, et al. Risk factors and treatment outcome of smear positive pulmonary tuberculosis patients: a five-year study in the north of Iran. Caspian J Intern Med 2024;15:347-53.
60. Hauer B, Brodhun B, Altmann D, Fiebig L, Loddenkemper R, Haas W. Tuberculosis in the elderly in Germany. Eur Respir J 2011;38:467-70.
61. Hochberg NS, Horsburgh CR Jr. Prevention of tuberculosis in older adults in the United States: obstacles and opportunities. Clin Infect Dis 2013;56:1240-7.
62. World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Available from: https://www.who.int/teams/global--tuberculosis-programme/tb-reports/globaltuberculosis-report-2022.
63. Yasobant S, Khatib MN, Syed ZQ, Gaidhane AM, Shah H, Narkhede K, et al. Health-related quality of life (HRQoL) of patients with tuberculosis: a review. Infect Dis Rep 2022;14:509-24.
64. Brown J, Capocci S, Smith C, Morris S, Abubakar I, -Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis 2015;32:68-75.
65. Septiani F, Erawati M, Suhartini. Factors affecting the quality of life among pulmonary tuberculosis patients: a literature review. Nurse Health J Keperawatan 2022;11:57-69.
66. Chang B, Wu AW, Hansel NN, Diette GB. Quality of life in tuberculosis: a review of the English language literature. Qual Life Res 2004;13:1633-42.
67. Sweetland AC, Kritski A, Oquendo MA, Sublette ME, Pala AN, Silva LRB, et al. Addressing the tuberculosis-depression syndemic to end the tuberculosis epidemic. Int J Tuberc Lung Dis 2017;21:852-61.
68. Lara-Espinosa JV, Hernández-Pando R. Psychiatric problems in pulmonary tuberculosis: depression and anxiety. J Tuberc Res 2021:31-50.
69. Sánchez-Pérez HJ, Gordillo-Marroquín C, Vázquez-Marcelín J, Martín-Mateo M, Gómez-Velasco A. Sociodemographic factors associated with the success or failure of anti-tuberculosis treatment in the Chiapas Highlands, Mexico, 2019–2022. PLoS One 2024;19:e0296924.
70. Braga S, Vieira M, Barbosa P, Ramos JP, Duarte R. -Tuberculosis screening in the European migrant population: a scoping review of current practices. Breathe (Sheff) 2024;20:230357.
71. Yerezhepov D, Gabdulkayum A, Akhmetova A, -Kozhamkulov U, Rakhimova S, Kairov U, et al. Pulmonary tuberculosis epidemiology and genetics in Kazakhstan. Front Public Health 2024;12:1340673.
72. Sánchez-Pérez HJ, Díaz-Vázquez A, Nájera-Ortiz JC, Balandrano S, Martín-Mateo M. Multidrug-resistant pulmonary tuberculosis in Los Altos, Selva and Norte regions, Chiapas, Mexico. Int J Tuberc Lung Dis 2010;14:34-9.
73. Pérez-Molina A, Sánchez-Pérez HJ, Yanes-Pérez M, Arana-Cedeño M. Tuberculosis care in Mexico’s Chiapas Highlands Region: a right to health analysis. Health Hum Rights 2020;22:305-16.
74. Kenya, Uganda, Zambia, and Zimbabwe TB Disability Study Group; Adakun SA, Banda FM, Bloom A, -Bochnowicz M, Chakaya J, Chansa A, et al. Disability, comorbidities and risk determinants at end of TB treatment in Kenya, Uganda, Zambia and Zimbabwe. IJTLD Open 2024;1:197-205.
75. Barreto-Duarte B, Villalva-Serra K, Miguez-Pinto JP, Araújo-Pereira M, Campos VMS, Rosier G, et al. Retreatment and anti-tuberculosis therapy outcomes in Brazil between 2015 and 2022: a nationwide study. Open Forum Infect Dis 2024;11:ofae416.
76. Matulyte E, Davidaviciene E, Kancauskiene Z, Diktanas S, Kausas A, Velyvyte D, et al. The socio--demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: a thirteen-year analysis. PLoS One 2023;18:e0282046.
77. Berihe Hiluf S, Abera A, Bahiru M, Kassie B. Determinants of unsuccessful tuberculosis treatment outcome in Southwest Ethiopia regional state public hospitals, 2022: a multi-center case control study. Front Public Health 2024;12:1406211.
78. International Diabetes Federation. IDF diabetes atlas reports [homepage on the Internet]. 2024. Available from: https://diabetesatlas.org/. Accessed February 29, 2024.
79. World Health Organization. Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
80. Noubiap JJ, Nansseu JR, Nyaga UF, Nkeck JR, Endomba FT, Kaze AD, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health 2019;7:e448-60.
81. Wu Q, Liu Y, Ma YB, Liu K, Chen SH. Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Med 2022;54:1657-66.
82. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. Int J Tuberc Lung Dis 2019;23:783-96.
83. Gautam S, Shrestha N, Mahato S, Nguyen TPA, Mishra SR, Berg-Beckhoff G. Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis. Sci Rep 2021;11:2113.
84. Nowin´ski A, Wesołowski S, Korzeniewska-Koseła M. The impact of comorbidities on tuberculosis treatment outcomes in Poland: a national cohort study. Front Public Health 2023;11:1253615.
85. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-72.
86. Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019;19:1129-37.
87. Bardenheier BH, Pavkov ME, Winston CA, Klosovsky A, Yen C, Benoit S, et al. Prevalence of tuberculosis disease among adult US-bound refugees with chronic kidney disease. J Immigr Minor Health 2019;21:1275-81.
88. Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy: a cohort study in Taiwan. Medicine (Baltimore) 2018;97:e12550.
89. Xiao J, Ge J, Zhang D, Lin X, Wang X, Peng L, et al. Clinical characteristics and outcomes in chronic kidney disease patients with tuberculosis in China: a retrospective cohort study. Int J Gen Med 2022;15:6661-9.
90. Pradhan RR, Sigdel MR. Prevalence, clinical presentation, and outcome of tuberculosis in patients with chronic kidney disease at a tertiary care hospital in Nepal. Int J Nephrol 2020;2020:7401541.
91. Ong CWM, Migliori GB, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, et al. Epidemic and pandemic viral infections: impact on tuberculosis and the lung: a consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and -Infectious Diseases Study Group for Mycobacterial -Infections -(ESGMYC). Eur Respir J 2020;56:2001727.
92. Western Cape Department of Health, National Institute for Communicable Diseases. Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa. Clin Infect Dis 2021;73:e2005-15.
93. Sy KTL, Haw NJL, Uy J. Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19. Infect Dis (Lond) 2020;52:902-7.
94. Global Tuberculosis Network and TB/COVID-19 Global Study Group. Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. Eur Respir J 2023;62:2300925.
95. Nalunjogi J, Mucching-Toscano S, Sibomana JP, Centis R, D’Ambrosio L, Alffenaar JW, et al. Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia: a Global Tuberculosis Network study. Int J Infect Dis 2023;130:S25-9.
96. Mundra A, Deshmukh PR, Dawale A. Magnitude and determinants of adverse treatment outcomes among tuberculosis patients registered under revised national tuberculosis control program in a tuberculosis unit, Wardha, Central India: a record-based cohort study. J Epidemiol Glob Health 2017;7:111-8.
97. Kant S, Singh A, Parmeshwaran G, Haldar P, Malhotra S, Kaur R. Delay in initiation of treatment after diagnosis of pulmonary tuberculosis in primary health care setting: eight-year cohort analysis from district Faridabad, Haryana, North India. Rural Remote Health 2017;17:1-8.
98. Ahmad S, Velhal G. Study of treatment interruption of new sputum smear positive TB cases under DOTS strategy. Int J Med Sci Public Health 2014;3:977-81.
99. Mittal C, Gupta S. Noncompliance to DOTS: how it can be decreased. Indian J Community Med 2011;36:27-30.
100. Krishnan A, Kapoor SK. Involvement of private practitioners in tuberculosis control in Ballabgarh, Northern India. Int J Tuberc Lung Dis 2006;10:264-9.
101. Chen EC, Owaisi R, Goldschmidt L, Maimets IK, Daftary A. Patient perceptions of video directly observed therapy for tuberculosis: a systematic review. J Clin Tuberc Other Mycobact Dis 2023;35:100406.
102. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
103. Ali A, Hasan Z, Jafri S, Inayat R, Hasan R. Mycobacterium tuberculosis Central Asian strain (CAS) lineage strains in Pakistan reveal lower diversity of MIRU loci than other strains. Int J Mycobacteriol 2014;3:108-16.
104. Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis 2018;18:249.
105. Jimma W, Ghazisaeedi M, Shahmoradi L, Abdurahman AA, Kalhori SRN, Nasehi M, et al. Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta--analysis. Rev Soc Bras Med Trop 2017;50:287-95.
106. Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant -tuberculosis: a global systematic review and meta-analysis. J Infect 2018;77:469-78.
107. Saifullah A, Mallhi TH, Khan YH, Iqbal MS, Alotaibi NH, Alzarea AI, et al. Evaluation of risk factors associated with the development of MDR- and XDR-TB in a tertiary care hospital: a retrospective cohort study. PeerJ 2021;9:e10826.
108. Mansoori N, Pahlavanzadeh B, Atarjalali M. Risk factors associated with multidrug-resistant tuberculosis in areas with a moderate tuberculosis burden. Int Health 2024;14:ihae039.
109. Chanda E. The clinical profile and outcomes of -drug--resistant tuberculosis in Central Province of -Zambia. BMC Infect Dis 2024;24:364.
110. Koo HK, Min J, Kim HW. Prediction of treatment failure and compliance in patients with tuberculosis. BMC Infect Dis 2020;20:622.
111. Dashuki AR, Ruzlin ANM, Zamzuri MAIA, Chen XW. Proportions and determinants of successful tuberculosis treatment among tuberculosis patients with comorbidity registered in National Tuberculosis Registry in Negeri Sembilan from year 2018–2023. Med J Malaysia 2024;80:50-9.
112. Sekandi JN, Buregyeya E, Zalwango S, Nakkonde D, Kaggwa P, Quach THT, et al. Effectiveness of a mobile health intervention (DOT selfie) in increasing treatment adherence monitoring and support for patients with tuberculosis in Uganda: randomized controlled trial. JMIR Mhealth Uhealth 2025;13:e57991.
113. Dos Santos LMAC, de Oliveira AM, Aguilar GJ, Dos Santos LRA, Costa WDL, Donato DCB, et al. Contribution of video directly observed therapy (VDOT) to tuberculosis treatment in Brazil. J Med Syst 2025;49:3.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
